NEW YORK, Nov. 6, 2017 /PRNewswire/ --
General Report Contents- Market Analyses include: Unit Sales, ASPs, Market Value & Growth TrendsRead the full report: https://www.reportlinker.com/p05175235- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsCurrent treatments of RA aim to relieve the symptoms of the disease and regain the maximum functionality of the damaged joint. There is no cure for rheumatoid arthritis. The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.DMARDs are a group of medications commonly used in patients with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. DMARDs work to reduce pain and inflammation, to prevent or minimize joint damage. They take effect over months and are not designed to provide immediate relief of symptoms.DMARDs can be prescribed along with nonsteroidal anti-inflammatory drugs and/or low-dose corticosteroids. Common DMARDs include methotrexate (Rheumatrex, Trexall, Otrexup, and Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine).Patients in more severe stages of the disease may need biologic response modifiers. These medications can block immune system chemical signals that lead to inflammation and joint damage. The biologic drugs include ORENCIA® (abatacept), HUMIRA® (adalimumab), Kineret® (Anakinra), CIMZIA® (certolizumab), ENBREL® (etanercept), SIMPONI® (golimumab), REMICADE® (infliximab), Rituxan® and MabThera® (rituximab) and Actemra® (tocilizumab).AbstractRheumatoid arthritis (RA) is a chronic systemic disease affecting joints, connective tissue, muscles, tendons and fibrous tissue. It is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints, leading to a painful swelling and destroys the cartilage and bone, resulting in permanent joint deformity.RA is one of the most disabling types of arthritis that causes joint pain, stiffness and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes RA can affect other organs, such as eyes, skin or even heart or lungs.Scope2014-2024Read the full report: https://www.reportlinker.com/p05175235 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
General Report Contents- Market Analyses include: Unit Sales, ASPs, Market Value & Growth TrendsRead the full report: https://www.reportlinker.com/p05175235- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsCurrent treatments of RA aim to relieve the symptoms of the disease and regain the maximum functionality of the damaged joint. There is no cure for rheumatoid arthritis. The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.DMARDs are a group of medications commonly used in patients with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. DMARDs work to reduce pain and inflammation, to prevent or minimize joint damage. They take effect over months and are not designed to provide immediate relief of symptoms.DMARDs can be prescribed along with nonsteroidal anti-inflammatory drugs and/or low-dose corticosteroids. Common DMARDs include methotrexate (Rheumatrex, Trexall, Otrexup, and Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine).Patients in more severe stages of the disease may need biologic response modifiers. These medications can block immune system chemical signals that lead to inflammation and joint damage. The biologic drugs include ORENCIA® (abatacept), HUMIRA® (adalimumab), Kineret® (Anakinra), CIMZIA® (certolizumab), ENBREL® (etanercept), SIMPONI® (golimumab), REMICADE® (infliximab), Rituxan® and MabThera® (rituximab) and Actemra® (tocilizumab).AbstractRheumatoid arthritis (RA) is a chronic systemic disease affecting joints, connective tissue, muscles, tendons and fibrous tissue. It is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints, leading to a painful swelling and destroys the cartilage and bone, resulting in permanent joint deformity.RA is one of the most disabling types of arthritis that causes joint pain, stiffness and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes RA can affect other organs, such as eyes, skin or even heart or lungs.Scope2014-2024Read the full report: https://www.reportlinker.com/p05175235 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/us-market-report-for-rheumatoid-arthritis-immunology-drugs-2018---medcore-300550603.html
SOURCE Reportlinker
